These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo. Ganapathi R, Grabowski D, Sweatman TW, Seshadri R, Israel M. Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093 [Abstract] [Full Text] [Related]
26. Cellular uptake and antitumor activity of the new anthracycline analog DA-125 in human cancer cell lines. Lim KH, Kim HS, Yang YM, Lee SD, Kim WB, Yang J, Park JG. Cancer Chemother Pharmacol; 1997 Dec; 40(1):23-30. PubMed ID: 9137525 [Abstract] [Full Text] [Related]
27. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells. Watanabe M, Komeshima N, Naito M, Isoe T, Otake N, Tsuruo T. Cancer Res; 1991 Jan 01; 51(1):157-61. PubMed ID: 1988080 [Abstract] [Full Text] [Related]
28. Evaluation of the in vitro antiproliferative properties of four novel anthracyclines YM1, 3, 4 and 6 in human leukemia cell lines. Jiang XR, Newland AC, Macey MG, Jenkins GC, Miki T, Adachi K, Yamabe S. J Chemother; 1992 Oct 01; 4(5):306-11. PubMed ID: 1479421 [Abstract] [Full Text] [Related]
29. [Models of preclinical studies of anthracyclines]. Fizames C. Pathol Biol (Paris); 1987 Jan 01; 35(1):41-8. PubMed ID: 3550611 [Abstract] [Full Text] [Related]
30. Induction of erythroid differentiation by the anthracycline antitumor antibiotic pyrromycin. Steinheider G, Schaefer A, Westendorf J, Marquardt H. Cell Biol Toxicol; 1988 Mar 01; 4(1):123-33. PubMed ID: 3228706 [Abstract] [Full Text] [Related]